Christian P. Behrenbruch
Co-Founder, MD, Group CEO & Executive DirectorDr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharmaceuticals Limited and served as its Interim CEO of Telix Americas since February 2022 Until July 11, 2022. He served as a Director of Amplia Therapeutics Pty Ltd. (formerly known as Innate Immunotherapeutics Ltd.) until February 6, 2020. Dr. Behrenbruch was Co -Founder at Amplia Therapeutics Limited. Dr. Behrenbruch was a Co-Founder of ImaginAb, Inc. and served as its Chief Executive Officer. He is a serial entrepreneur with a diverse background in developing and commercializing biotechnology, healthcare IT and medical devices from both the operational & executive perspective. Dr. Behrenbruch has healthcare entrepreneurship and executive leadership experience. He held positions as Chief Executive Officer and Executive Director include Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc. Dr. Behrenbruch has taken responsibility for establishing the initial operations and financing for ImaginAb. Dr. Behrenbruch served as Vice President at Siemens Molecular Imaging following the acquisition of Mirada Solutions and CTI Molecular Imaging, where he was responsible for advanced medical imaging research for lifesciences and clinical use. He served as Chairman of Cell Therapies Pty Ltd (a Partnership with the Peter MacCallum Cancer Centre). He has been an Executive Director of Telix Pharmaceuticals Limited since January 03, 2017. since May 4, 2018. He served as Non-Executive Director of Factor Therapeutics Limited since October 12, 2015 and served as an Independent Non-Executive Director since June 1, 2017 until May 28, 2021. He was a Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd., Radius Health Ltd (now Adaptix) and the Oncidium Foundation. He serves as Chairman of the Monash Engineering and IT Foundation Board. He is a Member of the Monash Engineering Foundation Board and serves as Adjunct Professor at Monash University and RMIT University. He is a Fellow of Engineers Australia in the management and biomedical colleges and a Graduate of the Australian Institute of Company Directors. He completed an engineering degree at Monash University, a D.Phil (Ph.D) in biomedical engineering from the University of Oxford, an MBA jointly awarded from New York University, Stern, HEC Paris and the London School of Economics (TRIUM Program) and a Juris Doctor (Law) from the University of Melbourne.
Positions
- Company NameTelix Pharmaceuticals LimitedStock CodeTLXPositionCo-Founder, MD, Group CEO & Executive DirectorColleagues
- DNDavid N. GillIndependent Non-Executive Chair of the Board
- DSDarren SmithGroup Chief Financial Officer
- DPDarren PattiGroup Chief Operating Officer
- DNDavid N. CadeGroup Chief Medical Officer
- PSPaul SchafferSVP of Research & Development
- MAMark Alexander NelsonIndependent Non-Executive Director
- JEJann Elizabeth SkinnerIndependent Non-Executive Director
- MEMarie E. McDonaldIndependent Non-Executive Director
